ValuEngine Lowers ImmuCell (ICCC) to Hold

ValuEngine cut shares of ImmuCell (NASDAQ:ICCC) from a buy rating to a hold rating in a research note published on Tuesday morning.

Separately, TheStreet upgraded ImmuCell from a d+ rating to a c rating in a research report on Tuesday, September 18th.

Shares of NASDAQ:ICCC traded down $0.18 on Tuesday, reaching $7.51. 424 shares of the company traded hands, compared to its average volume of 3,486. ImmuCell has a fifty-two week low of $6.50 and a fifty-two week high of $9.30. The company has a current ratio of 4.25, a quick ratio of 2.91 and a debt-to-equity ratio of 0.37.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Monday, August 13th. The biotechnology company reported ($0.05) EPS for the quarter. ImmuCell had a negative net margin of 14.07% and a negative return on equity of 4.36%. The company had revenue of $3.02 million for the quarter.

A hedge fund recently raised its stake in ImmuCell stock. Wells Fargo & Company MN grew its holdings in ImmuCell Co. (NASDAQ:ICCC) by 47.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,001 shares of the biotechnology company’s stock after purchasing an additional 11,000 shares during the period. Wells Fargo & Company MN owned approximately 0.62% of ImmuCell worth $238,000 as of its most recent SEC filing. Institutional investors own 13.72% of the company’s stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves.

Further Reading: What are trading strategies for the 52-week high/low?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with's FREE daily email newsletter.

Leave a Reply